SCHEMBL15047754

SCHEMBL15047754

Cc1cc(C)c(Br)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.36
KDM1B Q8NB78 2/20 0.36
BCHE P06276 1/20 0.33
CES1 P23141 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GPR3 P46089 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ACHE P22303 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
NFKB1 P19838 1/20 0.32
RAB9A P51151 1/20 0.32
NFKB2 Q00653 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565431 0.89 KDM1A (0.41) KDM1AKDM1BBCHECES1TSHR
SCHEMBL30578349 0.89 KDM1A (0.41) KDM1AKDM1BBCHECES1TSHR
SCHEMBL1224640 0.86 KDM1A (0.38) KDM1AKDM1BBCHECES1HDAC1
SCHEMBL29478809 0.86 KDM1A (0.38) KDM1AKDM1BBCHECES1HDAC1
SCHEMBL850836 0.83 KDM1A (0.50) KDM1AKDM1BBCHECES1TSHR
SCHEMBL30228644 0.83 KDM1A (0.45) KDM1AKDM1BHDAC1HDAC6GPR3
SCHEMBL1478306 0.83 KDM1A (0.45) KDM1AKDM1BHDAC1HDAC6GPR3
SCHEMBL26074270 0.79 CYP1A2 (0.33) KDM1AKDM1BCYP3A4TSHRMAPK1
SCHEMBL19491470 0.79 HTT (0.36) KDM1AKDM1BMEN1NPC1MAPT
SCHEMBL10147311 0.78 ACHE (0.40) CYP3A4TSHRMAPK1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020182990-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2020-09-17 WO disclosed
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-20130184257-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-07-18 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR39 KDM1A 1855/4885KDM1B 1595/4885BCHE 3351/4885
US-20130184257-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR180 KDM1A 2712/4885KDM1B 1870/4885BCHE 3573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.